✦ LIBER ✦

Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer

✍ Scribed by Djalalov, S.; Beca, J.; Hoch, J. S.; Krahn, M.; Tsao, M.-S.; Cutz, J.-C.; Leighl, N. B.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness of EML4-ALK Fusion Te

✍ Djalalov, S.; Beca, J.; Hoch, J.S.; Krahn, M.D.; Tsao, M.S.; Cutz, J.C.; Leighl, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Cost-Effectiveness Of Eml4-Alk Fusion Te

✍ Djalalov, S.; Hoch, J.S.; Beca, J.; Krahn, M.; Tsao, M.S.; Cutz, J.C.; Leighl, N 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Budget Impact Of Crizotinib For Alk-Posi

✍ Rosado-Buzzo, A.; Garcia-Mollinedo, L.; Luna-Casas, G.; Mould-Quevedo, J.F.; Gut 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Detection of EML4-ALK fusion genes in no

✍ Zhou Shaozhang; Lin Xiaomei; Zeng Aiping; He Jianbo; Song Xiangqun; Yu Qitao 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

369 Timing of responses to crizotinib (P

✍ B. Solomon; Y.J. Bang; D.R. Camidge; A.J. Iafrate; E.L. Kwak; R.G. Maki; S.I. Ou 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

3030 POSTER Preliminary Characterization

✍ B. Solomon; A. Chiappori; A. Lamb; M.C. Gawlicki; D.W. Kim; K. Park; R. Salgia; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB